Reduced plasma adiponectin in NASH: Central obesity as an underestimated causative risk factor
Uwe J. F. Tietge, Hartmut H.‐J. Schmidt, Tatjana Schütz, Patrizia Dippe, Herbert Lochs, Matthias Pirlich – 19 January 2005
p18(INK4c) expression in hepatocellular carcinoma
Tom Luedde, Frank Tacke, Michael P. Manns, Christian Trautwein – 19 January 2005
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis
Eduardo Schiffer, Chantal Housset, Wulfran Cacheux, Dominique Wendum, Christèle Desbois‐Mouthon, Colette Rey, François Clergue, Raoul Poupon, Véronique Barbu, Olivier Rosmorduc – 19 January 2005 – Epidermal growth factor receptor (EGFR) binds transforming growth factor α (TGF‐α) which is mitogenic for hepatocytes. Diverse lines of evidence suggest that activation of the TGF‐α /EGFR pathway contributes to hepatocellular carcinoma (HCC) formation.
Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol‐induced oxidative DNA damage in rodent liver
Blair U. Bradford, Hiroshi Kono, Fuyumi Isayama, Oksana Kosyk, Michael D. Wheeler, Taro E. Akiyama, Lisa Bleye, Kristopher W. Krausz, Frank J. Gonzalez, Dennis R. Koop, Ivan Rusyn – 19 January 2005 – The occurrence of malignant tumors of the upper gastrointestinal tract and liver is, based largely on epidemiological evidence, causally related to the consumption of ethanol. It is widely recognized that oxidants play a key role in alcohol‐induced liver injury; however, it is unclear how oxidants may be involved in DNA damage.
Optimizing outcomes and bridging biliary atresia into adulthood
Ronald J. Sokol, Cara L. Mack – 19 January 2005
Troglitazone and liver injury: In search of answers
Mario Chojkier – 19 January 2005
Peginterferon alfa‐2a for hepatitis C after liver transplantation: Two randomized, controlled trials
Naga Chalasani, Cosme Manzarbeitia, Peter Ferenci, Wolfgang Vogel, Robert J. Fontana, Michael Voigt, Caroline Riely, Paul Martin, Lewis Teperman, James Jiao, Juan Carlos Lopez‐Talavera – 19 January 2005 – There is currently no effective treatment for recurrent hepatitis C after orthotopic liver transplantation (OLT). We therefore performed two randomized, controlled trials—a prophylaxis trial and a treatment trial—to evaluate the safety and efficacy of peginterferon alfa‐2a in patients who had undergone OLT.
Hepatology highlights
Neil Kaplowitz – 19 January 2005
Preprocedure coagulation tests are unnecessary before abdominal paracentesis in emergency departments
Chih‐Hao Lin, Shyr‐Chyr Chen, Patrick Chow‐In Ko – 19 January 2005
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease
Shiobhan R. Weston, Wendy Leyden, Rose Murphy, Nathan M. Bass, Beth P. Bell, M. Michele Manos, Norah A. Terrault – 19 January 2005 – We performed a cross‐sectional study of newly diagnosed cases of nonalcoholic fatty liver disease (NAFLD) identified between December 1998 and December 2000 in the Chronic Liver Disease Surveillance Study. We compared the demographic and clinical features of NAFLD in a racially diverse representative U.S. population (Alameda County, CA).